Eli Lilly & Co
Eli Lilly & Co
LLY
XETR
837.10
EUR
-1.01%
About
Eli Lilly and Company is a medicine company. The Company discovers, develops, manufactures and markets products in the human pharmaceutical products segment. Its diabetes, obesity and other cardiometabolic products include Basaglar, Humalog, Mounjaro, Trulicity and Zepbound. Its oncology products include Alimta, Retevmo, Tyvyt and Verzenio.
Its immunology products include Ebglyss, Olumiant, Omvoh and Taltz. Its neuroscience products include Cymbalta and Emgality. Its other products and therapies include Cialis and Forteo. It manufactures and distributes its products through facilities in the United States (U.S.), including Puerto Rico, and in Europe and Asia.
The Company, through its subsidiary, POINT Biopharma Global Inc., is engaged in radiopharmaceutical discovery, development, and manufacturing, as well as clinical and pre-clinical radioligand therapies. It is also developing oral small molecule inhibitor of α4β7 integrin (known as MORF-057) for inflammatory bowel disease (IBD)..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 2.6M |
| Three Month Average Volume | 67.4M |
| High Low | |
| Fifty-Two Week High | 894.88944 EUR |
| Fifty-Two Week Low | 475.33036 EUR |
| Fifty-Two Week High Date | 22 Aug 2024 |
| Fifty-Two Week Low Date | 03 Oct 2023 |
| Price and Volume | |
| Current Price | 883.37816 EUR |
| Beta | 0 |
| Relative Price Change | |
| Four Week Relative Price Change | 12.96% |
| Thirteen Week Relative Price Change | 9.34% |
| Twenty-Six Week Relative Price Change | 11.63% |
| Fifty-Two Week Relative Price Change | 38.24% |
| Year-to-Date Relative Price Change | 39.07% |
| Price Change | |
| One Day Price Change | 2.11% |
| Thirteen Week Price Change | 17.03% |
| Twenty-Six Week Price Change | 22.75% |
| Five Day Price Change | 0.76% |
| Fifty-Two Week Price Change | 73.23% |
| Year-to-Date Price Change | 64.69% |
| Month-to-Date Price Change | 19.37% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 10.44045 EUR |
| Book Value Per Share (Most Recent Quarter) | 13.13035 EUR |
| Tangible Book Value Per Share (Last Fiscal Year) | -1.04134 EUR |
| Tangible Book Value Per Share (Most Recent Quarter) | 1.12085 EUR |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | 15.32838 EUR |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 34.76188 EUR |
| Revenue Per Share (Trailing Twelve Months) | 39.66674 EUR |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | 4.15915 EUR |
| Dividend Per Share (Trailing Twelve Months) | 4.47201 EUR |
| Dividend Per Share (5 Year) | 3.1985 EUR |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | 5.33835 EUR |
| Excluding Extraordinary Items (Trailing Twelve Months) | 7.47346 EUR |
| Normalized (Last Fiscal Year) | 9.2643 EUR |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | 5.35675 EUR |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | 7.50133 EUR |
| Including Extraordinary Items (Last Fiscal Year) | 5.33835 EUR |
| Including Extraordinary Items (Trailing Twelve Months) | 7.47346 EUR |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 2.83762 EUR |
| Cash Per Share (Most Recent Quarter) | 3.25693 EUR |
| Cash Flow Per Share (Last Fiscal Year) | 6.89419 EUR |
| Cash Flow Per Share (Trailing Twelve Months) | 9.12708 EUR |
| Free Cash Flow Per Share (Trailing Twelve Months) | -8.15698 EUR |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -1 |
| Cash Flow Revenue (Trailing Twelve Months) | -21 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | 23.10% |
| Pretax Margin (Last Fiscal Year) | 19.21% |
| Pretax Margin (5 Year) | 23.22% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | 79.25% |
| Gross Margin (Trailing Twelve Months) | 80.75% |
| Gross Margin (5 Year) | 77.34% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | 18.92% |
| Operating Margin (Trailing Twelve Months) | 23.28% |
| Operating Margin (5 Year) | 22.22% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | 15.36% |
| Net Profit Margin (Trailing Twelve Months) | 18.86% |
| Net Profit Margin (5 Year) | 20.24% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | 4.07% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | 35.98% |
| Revenue Growth (3 Year) | 9.69% |
| Revenue Change (Trailing Twelve Months) | 31.87% |
| Revenue Per Share Growth | 12.68% |
| Revenue Growth (5 Year) | 11.62% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | 19.62% |
| Total Debt (5 Year) | 19.62% |
| Dividends | |
| Dividend Growth (3 Year) | 15.15% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 67.99% |
| EPS Change (Trailing Twelve Months) | 12.84% |
| EPS Growth (3 Year) | 12.51% |
| EPS Growth (5 Year) | -5.10% |
| EBITDA | |
| EBITDA (5 Year) | 9.90% |
| EBITDA (5 Year Interim) | 16.76% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -0.15% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | -100,000 |
| Price to Tangible Book (Most Recent Quarter) | 788 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | 25.5B |
| Net Debt (Last Fiscal Year) | 22.3B |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 27 |
| Price to Sales (Trailing Twelve Months) | 23 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | 118 |
| PE Normalized (Last Fiscal Year) | 95 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | 111 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | 115 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | 23 |
| PE Including Extraordinary Items (Trailing Twelve Months) | 118 |
| Dividends | |
| Dividend Yield (5 Year) | 1.14% |
| Dividend Yield | 0.54% |
| Current Dividend Yield | 0.51% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 85 |
| Price to Book (Most Recent Quarter) | 67 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 170 |
| Long Term Debt to Equity (Most Recent Quarter) | 175 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | 80.55% |
| Payout Ratio (Trailing Twelve Months) | 61.62% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | 1 |
| Quick Ratio (Most Recent Quarter) | 1 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 1 |
| Current Ratio (Most Recent Quarter) | 1 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -7,221,300,000 |
| Free Cash Flow (Trailing Twelve Months) | -8,004,000,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | 31 |
| Net Interest Coverage (Trailing Twelve Months) | 25 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 234 |
| Total Debt to Equity (Most Recent Quarter) | 213 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | 9.23% |
| Return on Assets (Trailing Twelve Months) | 11.59% |
| Return on Assets (5 Year) | 11.71% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | 48.93% |
| Return on Equity (Trailing Twelve Months) | 59.63% |
| Return on Equity (5 Year) | 73.08% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | 15.22% |
| Return on Investment (Trailing Twelve Months) | 18.24% |
| Return on Investment (5 Year) | 17.33% |